A commonly used medication that prevents blood clots from forming may also prevent existing clots from damaging delicate vein walls — and may accelerate healing in a clot-damaged area of vein wall, according to new research from the University of Michigan Cardiovascular Center.

The Food and Drug Administration is highly concerned about Amgen's drug Nplate designed to treat a blood-clotting disorder.

Anemia drugs sold by Amgen Inc. and Johnson & Johnson increased the risk of blood clots and death in cancer patients, the largest study revealed.

Blood clots can save lives, staunching blood loss after injury, but they can also kill. Let loose in the bloodstream, a clot can cause a heart attack, stroke or pulmonary embolism.

Patients who develop a blood clot in their legs (deep vein thrombosis) or lungs (pulmonary embolism) are at risk for experiencing another blood clot within three years, and patients with pulmonary embolism have a higher risk of death, according to a report in the February 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

New techniques for detecting emboli (harmful blood clots/air bubbles in arteries) developed at the University of Leicester have played a major role in dramatically reducing stroke rates after carotid endarterectomy. This is an operation designed to remove narrowings in the main arteries supplying the brain before they can cause a stroke.

An intestinal protein known as BSDL that helps the body breakdown and absorb cholesterol is also found circulating in our bloodstream, where its role has been an enigma. However, in a new study, Laurence Panicot-Dubois and his colleagues at the Université de la Méditerranée, France, have identified a role for blood-borne BSDL in blood clot formation.

According to a new study published in Journal of Thrombosis and Haemostasis, regular participation in sports reduces the risk of developing blood clots by 39 percent in women and 22 percent in men.

Muscle relaxing drugs can effectively reduce Pulmonary Embolism (PE).

An international panel of researchers led by an oncologist from the Duke Comprehensive Cancer Center has put together a set of guidelines for the prevention and treatment of dangerous blood clots that threaten cancer patients.

Researchers at the University of Illinois at Chicago College of Medicine have identified a new molecular target in blood clot formation, which seems to reduce clotting without excessive bleeding, the common side-effect of anti-clotting agents.

Surgeons may have a new patient safety tool to stop moderate surgical bleeding without some of the concerns associated with the current standard blood-clotting treatment.